menu

FDA Confirms Leg and Foot Amputation Risk with Diabetes Medicine Canagliflozin

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free
FDA

FDA Confirms Leg and Foot Amputation Risk with Diabetes Medicine Canagliflozin

close
FDA Confirms Leg and Foot Amputation Risk with Diabetes Medicine Canagliflozin
Restart
Resume
Read full article
Choose a format
Media formats available:
Details
Comments
  • Overview

    Based on new data from two large clinical trials, the FDA concluded that the type 2 diabetes medicine canagliflozin (brand names Invokana, Invokamet, Invokamet XR) causes an increased risk of leg and foot amputations. The FDA is requiring new warnings, including their most prominent Boxed Warning, be added to the canagliflozin drug labels to describe this risk.

    Amputations of the toe and middle of the foot were the most common; however, amputations involving the leg, below and above the knee, also occurred. Some patients had more than one amputation, some involving both limbs.

    Report side effects involving canagliflozin and other medicines to the FDA MedWatch program at fda.gov/medwatch.

    A link to the full communication detailing specific information for health care professionals and the complete Data Summary can be found at fda.gov/DrugSafetyCommunications. If you have drug questions, contact the FDA at druginfo@fda.hhs.gov.

    Released 5/16/2017

Facebook Comments

Recommended
Details
Comments
  • Overview

    Based on new data from two large clinical trials, the FDA concluded that the type 2 diabetes medicine canagliflozin (brand names Invokana, Invokamet, Invokamet XR) causes an increased risk of leg and foot amputations. The FDA is requiring new warnings, including their most prominent Boxed Warning, be added to the canagliflozin drug labels to describe this risk.

    Amputations of the toe and middle of the foot were the most common; however, amputations involving the leg, below and above the knee, also occurred. Some patients had more than one amputation, some involving both limbs.

    Report side effects involving canagliflozin and other medicines to the FDA MedWatch program at fda.gov/medwatch.

    A link to the full communication detailing specific information for health care professionals and the complete Data Summary can be found at fda.gov/DrugSafetyCommunications. If you have drug questions, contact the FDA at druginfo@fda.hhs.gov.

    Released 5/16/2017

Facebook Comments

LIVE ON REACHMD RADIOBack to live radio

Loading...

Programs 9/29/20